Catalent Announces Supplying Blueprint Medicines' Precision Therapy AYVAKIT™ (avapritinib)
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: PR Web
SOMERSET, N.J. (PRWEB) February 27, 2020 Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell therapies, and consumer health products, welcomes the announcement by Blueprint Medicines Corporation that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.Catalent's Nottingham U.K. facility has supported Blueprint Medicines' development program since 2015, from formulation development, clinical product supply and now commercial supply of AYVAKIT."We are delighted to help support Blueprint Medicines with commercial supply for this important medicine, recently approved by the FDA, which provides a new treatment option for patients with this disease," com
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)Business Wire
- Citigroup Inc. (NYSE:C) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Citigroup (C) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Healthcare M&A Volume Falls in Q1:24, According to Acquisition Data from LevinPro HCPR Web
- Catalent, Inc. (NYSE: CTLT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
CTLT
Earnings
- 2/9/24 - Miss
CTLT
Sec Filings
- 4/15/24 - Form DEFM14A
- 4/9/24 - Form S-8
- 4/3/24 - Form PREM14A
- CTLT's page on the SEC website